← All trials
NCT06666335
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2024
- Primary completion
- Aug 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- Oct 30, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 3
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Swedish Orphan BiovitrumLead sponsor
- Tigermed Consulting Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.